LegisTrack
Back to all bills
HR 1432119th CongressIn Committee

LIABLE Act

Introduced: Feb 18, 2025
Standard Summary
Comprehensive overview in 1-2 paragraphs

The LIABLE Act would strip federal protections that currently shield COVID-19 vaccine manufacturers from certain lawsuits and liability limits. Specifically, no federal law could immunize a COVID-19 vaccine manufacturer from suit or cap its liability for losses caused by vaccination, and the act would apply to vaccines licensed or authorized by the FDA to prevent or mitigate COVID-19 or its transmission. The bill preserves, and explicitly coexists with, existing vaccine injury compensation programs (the Countermeasures Injury Compensation Program and the National Vaccine Injury Compensation Program), and it allows individuals to pursue civil suits even if they have sought compensation through those programs. The measure applies retroactively to vaccine administration before or after enactment. In short, the LIABLE Act would restore or maintain the ability for individuals to sue vaccine manufacturers in civil court for injuries related to a COVID-19 vaccine, while still enabling access to government-administered compensation programs as additional avenues for relief.

Key Points

  • 1Prohibits federal immunity or liability limitations for COVID-19 vaccine manufacturers, for claims arising from administration or use of a COVID-19 vaccine.
  • 2Explicitly preserves the option to seek compensation through the Countermeasures Injury Compensation Program (CICP) or the National Vaccine Injury Compensation Program (NVICP).
  • 3Clarifies that seeking compensation through CICP/NVICP does not bar or preclude bringing a civil action for the same claims.
  • 4Defines “COVID-19 vaccine” as any FDA-licensed or FDA-authorized vaccine intended to prevent, mitigate, or limit COVID-19 harm or the transmission of SARS-CoV-2 (or a related virus).
  • 5Retroactive applicability: the act applies regardless of when the vaccine was administered (before or after enactment).

Impact Areas

Primary group/area affected- COVID-19 vaccine manufacturers: potential liability exposure in civil court for injuries or losses linked to vaccine use.- Individuals injured by a COVID-19 vaccine: potential access to civil lawsuits as a remedy, in addition to existing compensation programs.- Healthcare providers and institutions: potential changes in risk exposure and legal dynamics around vaccine administration.Secondary group/area affected- Federal government and courts: changes to the landscape of vaccine-related litigation and the interaction with federal compensation programs.- Public health policy: potential influence on vaccine development, pricing, and availability if liability risk alters manufacturer decisions.Additional impacts- Financial implications: potential increase in litigation costs for manufacturers and possible shifts in compensation program utilization.- Legal/policy considerations: a shift away from broad federal immunity could affect the speed and manner in which vaccines are developed and deployed in future public health emergencies.- Public health outcomes: the balance between encouraging vaccine innovation and providing patient remedies could influence vaccine uptake and confidence? this depends on how litigation risk and compensation options interact in practice.
Generated by gpt-5-nano on Nov 18, 2025